CN112105349A - A2-73结晶多晶型物质组合物及其使用方法 - Google Patents
A2-73结晶多晶型物质组合物及其使用方法 Download PDFInfo
- Publication number
- CN112105349A CN112105349A CN201980031851.3A CN201980031851A CN112105349A CN 112105349 A CN112105349 A CN 112105349A CN 201980031851 A CN201980031851 A CN 201980031851A CN 112105349 A CN112105349 A CN 112105349A
- Authority
- CN
- China
- Prior art keywords
- crystalline
- formulation
- salt
- dosage form
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656435P | 2018-04-12 | 2018-04-12 | |
| US62/656,435 | 2018-04-12 | ||
| PCT/US2019/027369 WO2019200345A1 (en) | 2018-04-12 | 2019-04-12 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112105349A true CN112105349A (zh) | 2020-12-18 |
Family
ID=68163817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980031851.3A Pending CN112105349A (zh) | 2018-04-12 | 2019-04-12 | A2-73结晶多晶型物质组合物及其使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11498908B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773531A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7532718B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112105349A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019253028B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3096671C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019200345A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023208133A1 (zh) * | 2022-04-29 | 2023-11-02 | 苏州科睿思制药有限公司 | 布拉美森盐酸盐的晶型及其制备方法和用途 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
| WO2021158586A1 (en) | 2020-02-04 | 2021-08-12 | Teva Pharmaceuticals International Gmbh | Solid state forms of blarcamesine salts |
| US12018005B1 (en) | 2023-07-25 | 2024-06-25 | Egis Gyógyszergyár Zrt. | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103108631A (zh) * | 2010-06-15 | 2013-05-15 | 格吕伦塔尔有限公司 | 用于治疗疼痛的联合药物 |
| WO2017013498A2 (en) * | 2015-07-22 | 2017-01-26 | Anavex Life Sciences Corp. | Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions |
| CN107708687A (zh) * | 2015-07-22 | 2018-02-16 | 阿纳韦克斯生命科学公司 | 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体(ANAVEX2‑73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1002616B (el) * | 1996-02-21 | 1997-02-20 | Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης. | |
| WO2014159814A1 (en) * | 2013-03-13 | 2014-10-02 | Patricia Oliver | Formulations and tablets for treatment or prevention of neurological disorders |
| GR1008233B (el) * | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
| AU2016248376B2 (en) * | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| MX388953B (es) * | 2015-05-20 | 2025-03-20 | Ube Industries | Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo. |
| JP6866379B2 (ja) * | 2016-01-26 | 2021-04-28 | アナベックス ライフ サイエンシズ コーポレイション | 神経発達障害療法 |
| WO2017172784A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| CN111315375A (zh) * | 2017-06-14 | 2020-06-19 | 阿纳韦克斯生命科学公司 | 用于治疗阿尔茨海默病的anavex2-73 |
| AU2018375667B2 (en) * | 2017-11-28 | 2023-03-02 | Anavex Life Sciences Corp. | Sigma-1 receptor agonist systolic blood pressure therapy |
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
-
2019
- 2019-04-12 CN CN201980031851.3A patent/CN112105349A/zh active Pending
- 2019-04-12 CA CA3096671A patent/CA3096671C/en active Active
- 2019-04-12 CA CA3256071A patent/CA3256071A1/en active Pending
- 2019-04-12 EP EP19785595.0A patent/EP3773531A4/en active Pending
- 2019-04-12 US US17/046,929 patent/US11498908B2/en active Active
- 2019-04-12 WO PCT/US2019/027369 patent/WO2019200345A1/en not_active Ceased
- 2019-04-12 JP JP2020555811A patent/JP7532718B2/ja active Active
- 2019-04-12 AU AU2019253028A patent/AU2019253028B2/en active Active
-
2022
- 2022-11-01 US US17/978,818 patent/US12180174B2/en active Active
-
2024
- 2024-02-05 JP JP2024016033A patent/JP7758768B2/ja active Active
- 2024-08-02 AU AU2024205423A patent/AU2024205423B2/en active Active
- 2024-12-17 US US18/984,748 patent/US20250115566A1/en active Pending
-
2025
- 2025-06-23 JP JP2025105737A patent/JP2025131907A/ja active Pending
- 2025-10-09 JP JP2025171096A patent/JP2026004574A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103108631A (zh) * | 2010-06-15 | 2013-05-15 | 格吕伦塔尔有限公司 | 用于治疗疼痛的联合药物 |
| WO2017013498A2 (en) * | 2015-07-22 | 2017-01-26 | Anavex Life Sciences Corp. | Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions |
| CN107708687A (zh) * | 2015-07-22 | 2018-02-16 | 阿纳韦克斯生命科学公司 | 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体(ANAVEX2‑73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023208133A1 (zh) * | 2022-04-29 | 2023-11-02 | 苏州科睿思制药有限公司 | 布拉美森盐酸盐的晶型及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021521188A (ja) | 2021-08-26 |
| AU2024205423B2 (en) | 2026-06-25 |
| JP2025131907A (ja) | 2025-09-09 |
| US20230142424A1 (en) | 2023-05-11 |
| US11498908B2 (en) | 2022-11-15 |
| JP7532718B2 (ja) | 2024-08-14 |
| EP3773531A4 (en) | 2021-06-23 |
| AU2019253028A1 (en) | 2020-10-15 |
| CA3256071A1 (en) | 2025-10-31 |
| US12180174B2 (en) | 2024-12-31 |
| AU2019253028B2 (en) | 2024-05-30 |
| AU2024205423A1 (en) | 2024-08-22 |
| US20250115566A1 (en) | 2025-04-10 |
| JP2024038524A (ja) | 2024-03-19 |
| JP7758768B2 (ja) | 2025-10-22 |
| EP3773531A1 (en) | 2021-02-17 |
| US20210115004A1 (en) | 2021-04-22 |
| JP2026004574A (ja) | 2026-01-14 |
| CA3096671A1 (en) | 2019-10-17 |
| WO2019200345A1 (en) | 2019-10-17 |
| CA3096671C (en) | 2025-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7758768B2 (ja) | 物質のa2-73結晶多形組成物およびそれらの使用方法 | |
| AU2017213475B2 (en) | SecA inhibitors and methods of making and using thereof | |
| CN103945848A (zh) | 被取代的喹唑啉酮的口服即释制剂 | |
| EP3294719A1 (en) | Vortioxetine pyroglutamate | |
| ES2727577T5 (en) | Pharmaceutical composition containing an anti-nucleating agent | |
| BR112019010816A2 (pt) | composto de fórmula i, composto de fórmula ii, composto de fórmula iii, composto de fórmula iv, composto de fórmula v, composição farmacêutica, compostos, composto de fórmula viii, composto de fórmula ix, e composto de fórmula x | |
| DK2961391T3 (en) | Formulation comprising a benzothiazolone compound | |
| US10919906B2 (en) | Conformationally-constrained bioisosteres of caffeic acid, and synthesis and therapeutic uses | |
| CN118019541A (zh) | 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂 | |
| WO2012023145A2 (en) | Prasugrel hydrochloride crystalline particles | |
| WO2016114727A1 (en) | Cefditoren pivoxil compositions with improved stability and production methods thereof | |
| CN105017281A (zh) | 一类安妥沙星的盐及其制备方法和用途 | |
| JP7828354B2 (ja) | 中枢神経系への低疎水性の生物活性薬に対して化学的にカップリングされたトランスポーター | |
| CN119997948A (zh) | 用于预防退行性疾病引起的认知下降的组合物和方法 | |
| HK40045152B (en) | Crystalline epinephrine malonate salt | |
| HK1206736B (en) | Seca inhibitors and methods of making and using thereof | |
| HK1212213B (en) | Formulation comprising benzothiazolone compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: C. U. mishlin Inventor after: A. Selvi Inventor before: C. U. mishlin |